The Institute for Clinical and Economic Review's method of calculating drug cost-effectiveness using the quality-adjusted life years yielded by a treatment is one of the items it wants to look at as part of a formal re-evaluation of its framework for valuing new prescription drugs.
Another area targeted for review is the group's approach to assessing a drug's potential impact on overall US health care...






